- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03741101
Treatment of NF1-related Plexiform Neurofibroma With Trametinib (plexifpc)
Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain Relief
This trial, Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm,open-label study with the goals of volumetric partial remission and pain relief (EudraCT 2018-001846-32, Sponsor protocol number BUS2018-1, related Novartis reference number CTMT212ASE01T) is a pediatric clinical trial that investigates the potential use of the drug trametinib (Mekinist®) as treatment for symptomatic or likely to become symptomatic NF1-related plexiform neurofibromas (PN) in children between 1 year and 17 year and 11 months of age.
Trametinib is orally administered qd at 0.025 mg/kg up to a maximum of 2 mg from six years of age and 0.032mg/kilo up to 5 years of age, provided either as tablets or as oral solution. It is manufactured and distributed by Novartis under the trade name Mekinist®.
The primary endpoint is remission of tumor volume ≥20%, evaluated using volumetric MRI at 18 and 30 months of treatment.
The secondary endpoint is reversal of pain from NF1-related PN, evaluated monthly with agespecific pain scales; VAS scale (from 8 years) or Faces Pain Scale (from 3 to 8 years).
As an exploratory measure, the potential effects of the treatment on the cognitive function will be assessed using well-established tests such as WISC-V (age range 6:0 - 16:11), NEPSY-II (age range 3:0-16:11), and CPT-3 (age range 8:0 - adult).
Cognitive dysfunction is well described in patients with NF1, and the MAPK/ERK-pathway has been indicated to be involved in cognition.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lund, Sweden, 22241
- Skåne University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- NF1-related PN with severe - or with high suspicion of becoming severe - manifestations
- Informed consent provided
- Age 1:0-17:11
Exclusion Criteria
- NF1-related PN does not fulfill characteristics for acceptable volumetric MRI assessments as outlined under Criteria for volumetric assessment.
- Lactating or pregnant females. Sexually active females, who do not (agree to) use safe contraception or adhere to regular controls during study. Sexually active males who do not (agree to) use a condom during coitus.
- A history of other malignancies than classic NF1-related WHO grade 1 tumors (i.e. PN or optic pathway glioma).
- A history of NF-1 related cerebral vascular anomalies (such as Moyamoya).
- Active pharmaceutical therapy for optic pathway malignancy/ies.
- Any medication for treatment of left ventricular systolic dysfunction.
- Use of any investigational drug within 30 days of the first dose of this study treatment.
- Impaired renal function (GFR under 45 ml/min/1,73m2 - It is only required to analyze eGFR if creatine is above institutional reference value for corresponding age group).
- A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or excipients that contraindicate their participation.
- Active liver or biliary disease or moderate or severe liver impairment. If there are signs of liver disease (such as an increased prothrombin time or elevated transaminases),grading of the liver impairment has to be done in consultation with a hepatologist, since there is no universal definition.
- A history of hepatic sinusoid obstructive syndrome (venoocclusive disease) within the last 3 months.
- A history of heparin-induced thrombocytopenia.
- A history of interstitial lung disease or pneumonitis.
- A history of retinal vein occlusion (RVO).
- A history of Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. Subjects with a confirmed cleared HBV and HCV infection may be enrolled.
- Presence of a condition that will interfere significantly with the absorption of drugs.
- Evidence of cardiovascular risk, such as left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN), a corrected QT-interval (Qtc) >480 milliseconds, clinically significant uncontrolled arrhythmia, congestive heart failure, or acute coronary syndrome or history thereof.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm study
children treated with trametinib
|
treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Remission of tumor volume ≥20%
Time Frame: 0 - 30 months.
|
Final and primary analysis of primary outcome measure - of pooled data at 30 months (end of study) with volumetric mri of tumor volume versus volume at enrolment.
|
0 - 30 months.
|
Remission of tumor volume ≥20%
Time Frame: 0 - 18 months
|
Interim analysis of pooled data at 18 months with volumetric mri of tumor volume versus volume at enrolment.
This is an interim analysis of primary outcome and not primary analysis of primary outcome".
|
0 - 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reversal of NF1-related PN elicited - VAS scale pain
Time Frame: 0 - 30 months.
|
Evaluated with monthly VAS pain scale from 8 years at enrolment.
Monthly.
0-10 point scale.
Descriptive.
Analysis of pooled data after month 30.
|
0 - 30 months.
|
Reversal of NF1-related PN elicited pain - Faces Pain Scale
Time Frame: 0 - 30 months.
|
Evaluated with monthly Faces Pain Scale from under 8 years at enrolment.
Monthly.
0-10 scale.
Descriptive.
Analysis of pooled data after month 30.
|
0 - 30 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive performance. Exploratory. WISC V.
Time Frame: 0-18 months.
|
Change of full scale IQ or primary indexes of WISC V. Pooled data after 18 months versus before/at enrolment; with p-value <0.05.
|
0-18 months.
|
Cognitive performance. Exploratory. NEPSYII.
Time Frame: 0-18 months.
|
Change of Learning and Memory functions and visuospatial functions, pooled data after 18 months versus before/at enrolment (selected test from NEPSYII,; with p-value <0.05.
|
0-18 months.
|
Cognitive performance. Exploratory. CPT3.
Time Frame: 0-18 months.
|
Change in attention, pooled data after 18 months versus before/at enrolment (CPT-3); with p-value <0.05.
|
0-18 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Björn Sigurdsson, Skåne University Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Neurofibroma, Plexiform
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Trametinib
Other Study ID Numbers
- BUS2018-1
- 2018-001846-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Child
-
The Hospital for Sick ChildrenAga Khan University; March of DimesCompletedChild Development | Child Mortality | Child Morbidity | Child BehaviourPakistan
-
Boston Medical CenterCenter for the Study of Social PolicyCompletedChild Abuse | Parenting | Child Development | Child Rearing | Child NeglectUnited States
-
Oral Health Centre of Expertise in Western NorwayOral Health Center of Expertise Rogaland, Norway; Childrens advocacy center... and other collaboratorsRecruitingChild Abuse | Child Neglect | Child MaltreatmentNorway
-
University of Southern CaliforniaSafe Water and AIDS Project (SWAP); Early Childhood Development Network for...RecruitingChild Behavior | Child Development | Language, ChildKenya
-
Windward Islands Research and Education FoundationGrand Challenges Canada; St. George's University; GRENCASECompletedDevelopment, Child | Behavior, Child | Neurocognition, ChildGrenada
-
University of South CarolinaCompletedParents | Child Behavior | Child Health | Child, PreschoolUnited States
-
Milton S. Hershey Medical CenterRecruitingChild Abuse | Child Neglect | Child MaltreatmentUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingParent-Child Relations | Parenting | Child Behavior | Child MaltreatmentUnited States
-
Boston Medical CenterValhalla Foundation; Centering Healthcare Institute; Overdeck Family foundationRecruitingParent-Child Relations | Parenting | Child Behavior | Child DevelopmentUnited States
-
South London and Maudsley NHS Foundation TrustCarol Hardy, Research Lead, South London and Maudsley NHS FoundationCompletedChild Development | Parent Child Relationships | Parent Child InteractionsUnited Kingdom
Clinical Trials on Trametinib
-
Melanoma Institute AustraliaNovartisRecruiting
-
Memorial Sloan Kettering Cancer CenterCompletedNon Small Cell Lung Cancer | KRAS Gene MutationUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
Shanghai Henlius BiotechRecruiting
-
Stanford UniversityBoston Children's HospitalRecruitingArterial Disease | Venous MalformationUnited States
-
Adil DaudNational Comprehensive Cancer NetworkCompleted
-
The Netherlands Cancer InstituteGlaxoSmithKlineUnknown
-
University Health Network, TorontoNot yet recruitingArteriovenous Malformations
-
Leiden University Medical CenterNovartisRecruitingAnaplastic Thyroid CancerNetherlands